Verseon (LSE:VERS) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Verseon's annualized Gross Profit for the quarter that ended in Jun. 2019 was £0.00 Mil. Verseon's average Total Assets over the quarter that ended in Jun. 2019 was £44.99 Mil. Therefore, Verseon's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2019 was 0.00%.

Verseon Gross-Profit-to-Asset % Historical Data

The historical data trend for Verseon's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Gross-Profit-to-Asset % Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Verseon's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Verseon's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verseon's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verseon's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Verseon's Gross-Profit-to-Asset % falls into.

Verseon Gross-Profit-to-Asset % Calculation

Verseon's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2018 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2018 )	/	( (Total Assets (A: Dec. 2017 )	+	Total Assets (A: Dec. 2018 ))	/ count )
	=	0	/	( (40.4	+	44.524)	/ 2 )
	=	0	/	42.462
	=	0.00 %

Verseon's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2019 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2019 )	/	( (Total Assets (Q: Dec. 2018 )	+	Total Assets (Q: Jun. 2019 ))	/ count )
	=	0	/	( (44.524	+	45.459)	/ 2 )
	=	0	/	44.9915
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2019) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Verseon Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Verseon's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.